THERANEXUS presents its latest scientific news

09/09/2020
Dowload PDF File (711Ko)

Declaration of total number of shares and voting rights

07/09/2020
Dowload PDF File (295Ko)

THERANEXUS and BBDF obtain orphan drug designation (ODD) and Rare Paediatric Disease Designation (RPDD) from the Food And Drug Administration (FDA) for BBDF-101 for Batten disease

11/08/2020
Dowload PDF File (390Ko)

Declaration of total number of shares and voting rights

06/08/2020
Dowload PDF File (248Ko)

THERANEXUS to present the results of THN102 for Parkinson's Disease at the 2020 International Congress of Parkinson's Disease and Movement Disorders

30/07/2020
Dowload PDF File (643Ko)

THERANEXUS announces its cash position as of 30 June 2020 and implementation of a mandatory convertible bond facility

08/07/2020
Dowload PDF File (489Ko)

THERANEXUS secures €3.4m loan under the French state guarantee scheme (PGE) and provides an update on its developments

24/06/2020
Dowload PDF File (588Ko)

Declaration of total number of shares and voting rights

15/04/2020
Dowload PDF File (249Ko)

2019 full-year results and update on activities

09/04/2020
Dowload PDF File (351Ko)

Theranexus annouces the success of its phase 2 trial for THN102 in Parkinson's patients

31/03/2020
Dowload PDF File (351Ko)

Declaration of total number of shares and voting rights

04/02/2020
Dowload PDF File (272Ko)

THERANEXUS reports cash position as of December 31, 2019

27/01/2020
Télécharger le PDF (349Ko)

THERANEXUS announces its financial calendar for 2020

20/01/2020
Download PDF File (276Ko)

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

15/01/2020
Download PDF File (381 Ko)